Hematology

Clinical pharmacy services in hematology can have a significant impact, and the Pharmacy Times® Hematology resource center provides clinical news and articles about the topic. Here, visitors will find information about upcoming hematology conferences and meetings, updated clinical trial listings, and other resources.

What can we help you find?
[[thumbnail_alt_text]]
Myriad factors are involved in determining the appropriate care pathway for patients with acute myeloid leukemia.
 
[[thumbnail_alt_text]]
The importance of inpatient/outpatient (IPOP) unit induction and its role in the treatment of acute myeloid leukemia.
[[thumbnail_alt_text]]
Experts in AML discuss the impact of outpatient treatment options on the quality of life for patients and review available consolidation treatments.
[[thumbnail_alt_text]]
Experts in AML discuss the impact of outpatient treatment options on the quality of life for patients and review available consolidation treatments.
[[thumbnail_alt_text]]
Review of the pharmacist’s role in outpatient care for acute myeloid leukemia.
[[thumbnail_alt_text]]
The new formulation of twice-a-day deferiprone 1000 mg oral tablets eliminates the mid-day dose, and provides patients with the ability to reduce serum ferritin levels, and cardiac and liver iron.
[[thumbnail_alt_text]]
Description of the traditional inpatient administrations versus outpatient treatment processes in acute myeloid leukemia.
[[thumbnail_alt_text]]
The placement of clinical pharmacists at the nexus of functional pharmacogenomics and in specialty pharmacy care makes good sense. 
[[thumbnail_alt_text]]
Experts discuss the identification and Medical Utilization Evaluation of patients with newly diagnosed acute myeloid leukemia.
[[thumbnail_alt_text]]
Yehuda Deutsch, MD, and Amanda Brahim, PharmD, BCOP, BCPS, BCACP, review the risks and precautions taken with the available treatments of acute myeloid leukemia (AML).
 
[[thumbnail_alt_text]]
Options include Adakveo, Endari (L-glutamine oral powder), hydroxyurea (Droxia, Hydrea, Siklos), Oxbryta (voxelotor), as well as OTC medications, such as aspirin and ibuprofen.
 
[[thumbnail_alt_text]]
Amanda Brahim, PharmD, BCOP, BCPS, BCACP, discusses the members of her institution’s Pharmacy and Therapeutics (P&T) Committee who review acute myeloid leukemia treatments for formulary consideration.